middle.news
How Percheron’s HMBD-002 Is Shaping Up After Positive Phase I Results
9:05am on Friday 31st of October, 2025 AEDT
•
Biotechnology
Read Story
How Percheron’s HMBD-002 Is Shaping Up After Positive Phase I Results
9:05am on Friday 31st of October, 2025 AEDT
Key Points
Positive phase I clinical trial data for HMBD-002 with favorable safety profile
Promising preclinical results in triple-negative breast cancer and head & neck cancer
Multi-arm phase II clinical trial design announced, targeting multiple tumor types
Transfer of IND sponsorship to Percheron completed with US FDA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE